Literature DB >> 18370757

Mild gestational hyperglycemia and the metabolic syndrome in later life.

Simona Bo1, Guido Menato, Chiara Botto, Ilenia Cotrino, Chiara Bardelli, Roberto Gambino, Maurizio Cassader, Marilena Durazzo, Anna Signorile, Marco Massobrio, Gianfranco Pagano.   

Abstract

BACKGROUND: Diabetes and obesity, components of the metabolic syndrome, are common longterm complications in women with previous gestational diabetes (pGDM). Long-term follow-up of women with mild gestational hyperglycemia is lacking.
METHODS: Fifty women with previous positive oral glucose challenge test and negative oral glucose tolerance test (pOGCT+OGTT-), 161 with previous normal glucose tolerance (pNGT), and 182 pGDM were studied after 6.5 years from the index pregnancy.
RESULTS: Patients with pGDM showed a worse metabolic pattern than pNGT. Women with pOGCT+OGTT- had significantly higher levels of fasting glucose, homeostasis model assessment (HOMA), percentage of impaired fasting glucose, and low age and high-density lipoprotein (HDL)-cholesterol than pNGT subjects. Prevalence of the metabolic syndrome (MS) was, respectively, sixfold and twofold higher in pGDM and pOGCT+OGTT- than in pNGT. In a Cox proportional hazard model, after multiple adjustments, pGDM was significantly associated with subsequent hyperglycemia (hazard ratio [HR] = 4.2; 95% CI 1.6-11.1), low HDL-cholesterol (HR = 1.7, 1.1-2.8), hypertriglyceridemia (HR = 4.2, 1.2-14.9), hypertension (HR = 2.2, 1.3-3.6), MS (HR = 3.7, 1.3-10.8), while pOGCT+OGTT- was associated with subsequent hyperglycemia (HR = 4.3, 1.3-14.7), and low HDL-cholesterol (HR = 2.0, 1.0-3.8). The metabolic syndrome was present in 52.6% of obese pGDM, 50% of obese pOGCT+OGTT-, and 28.6% of obese pNGT women; the corresponding HRs were, respectively, HR = 2.20, 0.74-6.57 (pGDM), and HR = 3.56, 1.10-11.5 (pOGCT+OGTT-).
CONCLUSIONS: Women who failed the OGCT, but not the OGTT, showed a subsequent worse metabolic pattern than pNGT subjects, independently of confounding factors. In the presence of obesity, the prevalence of the metabolic syndrome was similar to that of obese pGDM women, and almost twofold higher than in obese pNGT controls.

Entities:  

Year:  2006        PMID: 18370757     DOI: 10.1089/met.2006.4.113

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  6 in total

Review 1.  Risk of developing metabolic syndrome after gestational diabetes mellitus - a systematic review and meta-analysis.

Authors:  A Tranidou; T Dagklis; I Tsakiridis; A Siargkas; A Apostolopoulou; A Mamopoulos; D G Goulis; M Chourdakis
Journal:  J Endocrinol Invest       Date:  2020-11-23       Impact factor: 4.256

2.  Association between metabolic syndrome and gestational diabetes mellitus in women and their children: a systematic review and meta-analysis.

Authors:  Maleesa M Pathirana; Zohra S Lassi; Anna Ali; Margaret A Arstall; Claire T Roberts; Prabha H Andraweera
Journal:  Endocrine       Date:  2020-09-15       Impact factor: 3.633

3.  Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women.

Authors:  Ravi Retnakaran; Ying Qi; Philip W Connelly; Mathew Sermer; Bernard Zinman; Anthony J G Hanley
Journal:  J Clin Endocrinol Metab       Date:  2009-11-19       Impact factor: 5.958

Review 4.  [What does the obstetrician expect from the internist during prenatal care?].

Authors:  K T M Schneider
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

Review 5.  Metabolic syndrome risk after gestational diabetes: a systematic review and meta-analysis.

Authors:  Yuhong Xu; Shutong Shen; Lizhou Sun; Haiwei Yang; Bai Jin; Xiaohui Cao
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

6.  Serum adiponectin level and clinical, metabolic, and hormonal markers in patients with polycystic ovary syndrome.

Authors:  Yunus Yildiz; Gülnur Ozaksit; Bekir Serdar Unlu; Emre Ozgu; Hasan Energin; Metin Kaba; Mustafa Ugur
Journal:  Int J Fertil Steril       Date:  2013-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.